ANGO - AngioDynamics, Inc.
NASDAQ
->
Healthcare
->
Medical Instruments & Supplies
Latham,
United States
Type: Equity
ANGO price evolution
ANGO
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $78.45 | $60.9 | $57.59 | $44.62 |
| Short term investments | ||||
| Net receivables | $49.48 | $51.6 | $49.76 | $52.83 |
| Inventory | $58.07 | $64.25 | $59.97 | $55.33 |
| Total current assets | $196.91 | $185.47 | $175.47 | $163.54 |
| Long term investments | ||||
| Property, plant & equipment | $37.04 | $42.56 | $43.36 | $44.38 |
| Goodwill & intangible assets | $81.57 | $263.12 | $265.69 | $270.38 |
| Total noncurrent assets | $127.94 | $314.15 | $318.47 | $369.1 |
| Total investments | ||||
| Total assets | $324.84 | $499.62 | $493.95 | $532.64 |
| Current liabilities | ||||
| Accounts payable | $35.15 | $37.65 | $24.81 | $40.45 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $85.87 | $78.04 | $57.45 | $83.83 |
| Long term debt | $49.82 | |||
| Total noncurrent liabilities | $20.27 | $20.36 | $8.69 | $70.52 |
| Total debt | $49.82 | |||
| Total liabilities | $106.14 | $98.4 | $66.14 | $154.34 |
| Shareholders' equity | ||||
| Retained earnings | -$381.75 | -$194.02 | -$164.97 | -$210.85 |
| Other shareholder equity | -$2.81 | -$4.71 | -$5.65 | $378.3 |
| Total shareholder equity | $218.7 | $401.23 | $427.8 | $378.3 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.62 | $28.82 | $48.16 | $54.44 |
| Short term investments | ||||
| Net receivables | $52.83 | $52.3 | $35.41 | $31.26 |
| Inventory | $55.33 | $51.39 | $48.61 | $59.91 |
| Total current assets | $163.54 | $143.34 | $140.88 | $152.91 |
| Long term investments | ||||
| Property, plant & equipment | $44.38 | $45.01 | $37.07 | $28.31 |
| Goodwill & intangible assets | $270.38 | $353.44 | $370.29 | $397.65 |
| Total noncurrent assets | $369.1 | $409.41 | $420.56 | $441.3 |
| Total investments | ||||
| Total assets | $532.64 | $552.75 | $561.44 | $594.21 |
| Current liabilities | ||||
| Accounts payable | $40.45 | $28.05 | $19.63 | $19.1 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $83.83 | $74.32 | $57.58 | $51.45 |
| Long term debt | $49.82 | $25 | $20 | $40 |
| Total noncurrent liabilities | $70.52 | $53.94 | $64.4 | $87.9 |
| Total debt | $49.82 | $25 | $20 | $40 |
| Total liabilities | $154.34 | $128.26 | $121.98 | $139.34 |
| Shareholders' equity | ||||
| Retained earnings | -$210.85 | -$158.41 | -$131.87 | -$100.32 |
| Other shareholder equity | $378.3 | $1.36 | $3.15 | -$1.34 |
| Total shareholder equity | $378.3 | $424.49 | $439.46 | $454.87 |
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Sep 2023 | 1 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.68 | $91.07 | ||
| Cost of revenue | $38.62 | |||
| Gross Profit | $40.06 | $46.36 | ||
| Operating activities | ||||
| Research & development | $7.94 | |||
| Selling, general & administrative | $38.22 | |||
| Total operating expenses | $5.16 | $49.02 | ||
| Operating income | $34.9 | |||
| Income from continuing operations | ||||
| EBIT | $34.74 | |||
| Income tax expense | -$11.02 | -$0.4 | ||
| Interest expense | -$0.12 | -$0.9 | ||
| Net income | ||||
| Net income | $45.88 | -$21.47 | ||
| Income (for common shares) | $45.88 | |||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $291.01 | $264.16 | ||
| Cost of revenue | $134.22 | $113.89 | ||
| Gross Profit | $156.79 | $150.27 | ||
| Operating activities | ||||
| Research & development | $36.39 | $29.68 | ||
| Selling, general & administrative | $117.22 | $116.51 | ||
| Total operating expenses | $191.89 | $328.9 | ||
| Operating income | -$35.1 | -$178.63 | ||
| Income from continuing operations | ||||
| EBIT | -$35.19 | -$167.23 | ||
| Income tax expense | -$4.5 | -$1.35 | ||
| Interest expense | $0.86 | $0.91 | ||
| Net income | ||||
| Net income | -$31.55 | -$166.79 | ||
| Income (for common shares) | -$31.55 | -$166.79 | ||
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 1 Jul 2023 |
|---|---|---|---|---|
| Net income | -$187.74 | -$29.05 | $45.88 | |
| Operating activities | ||||
| Depreciation | $8.01 | $7.17 | $7.16 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.61 | $1.88 | $4.14 | |
| Total cash flows from operations | -$12.53 | $5.27 | -$25.9 | |
| Investing activities | ||||
| Capital expenditures | $32.65 | -$1.79 | $98.44 | |
| Investments | ||||
| Total cash flows from investing | $29.4 | -$1.79 | $98.44 | -$9.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.69 | -$0.35 | $0.41 | |
| Net borrowings | -$50 | |||
| Total cash flows from financing | $0.69 | -$0.35 | -$59.59 | $25.42 |
| Effect of exchange rate | -$0.02 | $0.19 | $0.01 | $0.04 |
| Change in cash and equivalents | $17.55 | $3.31 | $12.97 | $15.79 |
| (in millions $) | 1 Jul 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$26.55 | -$31.55 | -$166.79 | |
| Operating activities | ||||
| Depreciation | $31.79 | $28.37 | $25.88 | |
| Business acquisitions & disposals | -$3.6 | -$55.76 | ||
| Stock-based compensation | $10.69 | $8.63 | $7.59 | |
| Total cash flows from operations | -$7.19 | $24.09 | -$14.55 | |
| Investing activities | ||||
| Capital expenditures | -$15.71 | -$13.71 | -$7.24 | |
| Investments | ||||
| Total cash flows from investing | -$9.75 | -$19.31 | -$13.71 | -$63.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.68 | $3.01 | -$0.76 | |
| Net borrowings | $5 | -$20 | -$92.5 | |
| Total cash flows from financing | $25.42 | $7.68 | -$16.99 | -$95.24 |
| Effect of exchange rate | $0.04 | -$0.52 | $0.33 | -$0.07 |
| Change in cash and equivalents | $15.79 | -$19.34 | -$6.27 | -$173.21 |
News
|
Insider Spends US$67k Buying More Shares In AngioDynamics
Simply Wall St. via Yahoo Finance
10 Apr 2024
|
|
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance
8 Apr 2024
|
|
AngioDynamics CEO buys $67,000 worth of company stock By Investing.com
Investing.com
8 Apr 2024
|
|
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance
5 Apr 2024
|
|
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
Zacks via Yahoo Finance
5 Apr 2024
|
|
AngioDynamics: Fiscal Q3 Earnings Snapshot
Washington Post
4 Apr 2024
|
|
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
Benzinga via Yahoo Finance
4 Apr 2024
|
|
AngioDynamics gets FDA clearance for pulmonary embolism treatment device (NASDAQ:ANGO)
Seeking Alpha
4 Apr 2024
|
|
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
Zacks
4 Apr 2024
|
|
AngioDynamics (ANGO) Settles Patent Litigations With BD
Zacks via Yahoo Finance
2 Apr 2024
|
Fundamentals
| Market cap | $243.91M |
|---|---|
| Enterprise value | $165.46M |
| Shares outstanding | 39.86M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.10 |
| Book/Share | 5.56 |
| Cash/Share | 1.97 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.41 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.29 |
| Quick ratio | 1.62 |